Related Experiment Videos
Effects of long-term ticlopidine treatment on platelet function and its tolerability in cerebrovascular disease
Insights
Ticlopidine effectively reduced platelet aggregation and adhesiveness in patients with cerebrovascular disease. This new antiplatelet drug demonstrated safety during a 6-month trial, offering a potential treatment option.
Area of Science:
- Pharmacology
- Neurology
- Cardiovascular Medicine
Background:
- Cerebrovascular disease, including transient ischemic attack (TIA) and stroke, poses significant health risks.
- Platelet aggregation plays a critical role in the pathophysiology of thrombotic events associated with cerebrovascular disease.
- Effective antiplatelet therapies are crucial for managing and preventing recurrent vascular events.
Purpose of the Study:
- To evaluate the efficacy of ticlopidine, a novel platelet aggregation inhibitor, in patients with cerebrovascular disease.
- To assess the impact of ticlopidine on specific platelet functions and coagulation parameters.
- To determine the safety profile of ticlopidine during long-term administration (6 months).
Main Methods:
- A clinical trial involving thirty-two patients diagnosed with cerebrovascular disease (TIA and stroke).
- Administration of ticlopidine for a duration of 6 months.
- Assessment of platelet functions, including ADP-induced platelet aggregation and platelet adhesiveness, alongside coagulation markers.
Main Results:
- Ticlopidine demonstrated high effectiveness in inhibiting ADP-induced platelet aggregation.
- Significant reduction in platelet adhesiveness and circulating platelet aggregates was observed.
- No significant impact on fibrinogen levels and no serious adverse side-effects were reported during the trial.
Conclusions:
- Ticlopidine is a potent inhibitor of key platelet functions relevant to thrombotic events.
- The drug exhibits a favorable safety profile for long-term use in patients with cerebrovascular disease.
- Ticlopidine shows promise as a valuable therapeutic agent in the management of patients suffering from cerebrovascular conditions.
Abstract:
A trial was performed on thirty-two patients with cerebrovascular disease (transient ischaemic attack and stroke) to assess the effect of ticlopidine, a new inhibitor of platelet aggregation, on some platelet functions and coagulation, and its safety in long-term use (6 months). The results show that ticlopidine was highly effective in inhibiting ADP-induced platelet aggregation, platelet adhesiveness and circulating platelet aggregates, but it had no effect on fibrinogen levels. No serious side-effects were observed. Ticlopidine may therefore prove to be a useful antiplatelet drug in the management of patients with cerebrovascular disease.